After carefully reviewing the data known from the presentation, I am becoming more confident DCVax-L will get approved for both nGBM and rGBM by all RAs concerned, simply because the data has demonstrated efficaciousness plus the pristine safety profile of the treatment, and manufacturing readiness.
Going into this presentation, my confidence level was about 65%, today 80%. I also believe and it is logic the imminent publication will have some more compelling evidences of efficaciousness than what presentation contains. So I believe my confident level will increase accordingly.
Any investors should remember this disease is one of the toughest if not the toughest to conquer. Over the past decades, drugs giving a mere 1.5-2 months of OS benefit with much more severe side effects had got approved.
The essential and promising role of DCVax-L which it will play in ultimately conquering the cancers via combination with other approved drugs/agents will be also a factor in consideration of approval.
So at this level of price, I am definitely a buyer. Accumulation of shares takes some time before it's too late to get in cheap. Any day forward is our day I believe.
Thinking about those tens of millions of shares sold in the previous days in prices from $1.9 range all the way down to $0.3. Those shares alone will be bought to cover for the short, repurchased by those sold in panic, ... as data is being digested, let alone the market awareness after the presentation which will draw in new investors.
BTW, for those asking the question, Hodag is a poster over iVilliage who is always wearing a pair of glasses on anything concerning nwbo. He is a little more subtle than most plain bears over their or in this board but always tries to find fault, existing or not regarding nwbo.
